Skip to main content
Clinical Trials/NCT04766489
NCT04766489
Completed
Not Applicable

Evaluation of the Treatment Response in Breast Cancer Related Lymphedema After Mastectomy Surgery

Ege University1 site in 1 country30 target enrollmentJuly 11, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphedema of Upper Limb
Sponsor
Ege University
Enrollment
30
Locations
1
Primary Endpoint
CLUE score
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study aims to evaluate the effects of the treatment for breast cancer lymphedema. After taking a detailed history and giving a physical examination, breast cancer related lymphedema patients(n:30) will be informed and will be given Complete Decongestive Therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise. Patients will be evaluated with limb volume, lymphedema index acquired through bioimpedance device, QuickDASH for upper extremity function, hand dynamometer for upper extremity grip strength and CLUE(Breast Cancer-Related Lymphedema of the Upper Extremity standardized clinical evaluation tool) scoring for lymphedema before and after the intervention. The values will be compared in order to show whether there are significant differences between before and after scores, and whether CLUE score is correlated with the other indicators of breast cancer related lymphedema.

Registry
clinicaltrials.gov
Start Date
July 11, 2019
End Date
December 11, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Göksel Tanıgör M.D.

Researcher

Ege University

Eligibility Criteria

Inclusion Criteria

  • Unilateral lymphedema of the arm after mastectomy for breast cancer

Exclusion Criteria

  • Bilateral lymphedema
  • Primary bone tumor and/or metastasis
  • Patients with ongoing radiotherapy
  • Circulation disorders of the upper extremity(eg; peripheral vascular disease, thrombosis)
  • Patients with infectious lymphedema/elephantiasis
  • Presence of local infection in upper extremities(cellulitis) and/or presence of severe systemic infection
  • Carcinomatous lymphangitis
  • Congestive heart failure(NYHA class 3 or 4)
  • History of prosthesis on upper extremities
  • Use of drugs which may alter the fluid or electrolyte balance

Outcomes

Primary Outcomes

CLUE score

Time Frame: 1 month

Breast Cancer-Related Lymphedema of the Upper Extremity (CLUE) is a standardized clinical evaluation tool which was developed to evaluate the severity of the lymphedema, especially in the context of clinical trials. CLUE involves assessing obscuration of anatomical architecture (eg, bony prominences, tendons), deviation from normal anatomical contour, change of soft-tissue texture, and the presence of pitting or nonpitting edema. It consists of these four assessments conducted in three different parts or the upper extremity(arm, forearm and hand). CLUE scores have a range of 0 to 72, with greater numbers associated with more severe lymphedema. It was shown to be valid and reliable for the assessment of breast cancer related lymphedema by Spinelli et al.(1)

Secondary Outcomes

  • QuickDASH(1 Month)
  • Extremity volume(1 Month)
  • Lymphedema index(1 Month)
  • Hand Grip Strength(1 Month)

Study Sites (1)

Loading locations...

Similar Trials